Fredrik Müller

ORCID: 0000-0003-0812-0640
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • COVID-19 Clinical Research Studies
  • Immune Cell Function and Interaction
  • Long-Term Effects of COVID-19
  • COVID-19 and healthcare impacts
  • HIV-related health complications and treatments
  • HIV Research and Treatment
  • IL-33, ST2, and ILC Pathways
  • Carcinogens and Genotoxicity Assessment
  • Sepsis Diagnosis and Treatment
  • SARS-CoV-2 and COVID-19 Research

Oslo University Hospital
1999-2024

University of Oxford
2021

University of Oslo
1999-2017

The Research Council of Norway
1999

In-Q-Tel
1999

Objective: To study the progression of HIV infection in relation to immunological and virological variables with emphasis on role CD8+ lymphocytes. Design: Prospective follow-up from October 1991 patients observed for at least 18 months allowing nucleoside analogue monotherapy. Peripheral CD4+ lymphocyte counts, RNA, soluble CD8 were analysed by statistics evaluation serial data, avoiding time points concurrent infections. Setting: Tertiary university clinic. Patients: Forty-nine followed...

10.1097/00002030-199902040-00007 article EN AIDS 1999-02-01

IL-33, required for viral clearance by cytotoxic T cells, is generally expressed in vascular endothelial cells healthy human tissues. We discovered that IL-33 expression was stimulated as a response to adenoviral transduction. This dependent on MRE11, sensor of DNA damage can also be activated DNA, and IRF1, transcriptional regulator cellular responses invasion damage. Accordingly, we observed responded phosphorylation ATM CHK2 depletion or inhibition but not ATM, abrogated stimulation. In...

10.4049/jimmunol.1600054 article EN The Journal of Immunology 2017-03-04
Coming Soon ...